Hybrid clinical trials combine traditional site-based research with decentralized trial (DCT) elements. These can include remote monitoring via apps and wearable technology, as well as virtual...
Read More
The most powerful shift in clinical research this year:Bringing the clinic to the patient is no longer optional; it's essential for patient enrollment and retention. 2025 proved that sponsors don't...
Read More
Why Diversity in Clinical Trials Remains a Critical Gap Diversity in clinical trials is vital to ensure treatments are safe for everyone. Clinical trial participants come from all backgrounds,...
Read More
BCVA can partially work in a virtual setting with validated digital tools and telemedicine oversight, but usually still benefits from a controlled, in-person environment. OCT essentially requires...
Read More
When an enrolled trial population doesn't reflect how a condition is actually treated in the real world, the consequences show up well after approval: narrower labels, closer safety scrutiny, and...
Read More
One of the most overlooked challenges in clinical research is the travel distance required of participants. According to the American Society of Clinical Oncology (ASCO), over half of oncology trial...
Read More
Why Retention Matters More Than Ever GLP-1 programs often include extended ocular safety follow-up (e.g., 24–36 months). Sustained retention preserves statistical power and reduces bias; across...
Read More
Sponsors can expand ocular endpoint assessment capacity without new construction by combining five approaches: mobile vision clinics, modular on-site augmentation, distributed assessment networks,...
Read More